24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Hospitals & Clinics
specialties & services
Dr. Weijing Sun graduated medical school from Shanghai Medical University and completed his residency at Loyola University. A fellowship in hematology/oncology followed at University of Pennsylvania Health System. Dr. Sun is specialized and board certified in medical oncology. He has been in practice for more than 20 years and is affiliated with University of Pittsburgh Medical Center. Moreover, during his career, he has run multiple clinical trials and has published several writings of medical interest in collaboration with other doctors.
Shanghai Medical University Graduated in 1982
Medical School
Loyola University Med Center Completed in 1996
Internship
Loyola University Med Center Completed in 1998
Residency
Perelman School of Medicine University of Pennsylvania Completed in 2001
Fellowship
American Board of Internal Medicine - Oncology
Magee Womens Hospital of UPMC Pittsburgh
Languages: English/Spanish
(412) 641-1000
300 Halket St
Pittsburgh, Pennsylvania 15213 
UPMC Presbyterian Shadyside
Languages: English/Spanish
(412) 647–2345
200 Lothrop Street
Pittsburgh, Pennsylvania 15213-2536
UPMC Shadyside
Languages: English/Spanish
(412) 623-2121
5230 Centre Ave
Pittsburgh, Pennsylvania 15232
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma
Ciuleanu T, Bazin I, Lungulescu D, Miron L, Bondarenko I, Deptala A, Rodriguez-Torres M, Giantonio B, Fox NL, Wissel P, Egger J, Ding M, Kalyani RN, Humphreys R, Gribbin M, Sun W
See more >>
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced and metastatic cholangiocarcinoma
Sohal DS, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W
See more >>
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-Xuorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
Sun W, Metz J, Gallagher M, O'Dwyer PJ, Whittington R, Giantonio B, Haller DG
See more >>Memberships
American Association for Cancer Research
American Society of Clinical Oncology
